Category Archives: Mesenchymal Stem Cells

Contact Information Available for logged-in reporters only Newswise Scientists from UCLAs Eli and Edythe Broad Center of Regenerative Medicine and Stem Cell Research have received new awards from the California Institute of Regenerative Medicine (CIRM), the state stem cell research agency, that will forward revolutionary stem cell science in medicine. Recipients included Dr. Lili Yang, assistant professor of microbiology, immunology and molecular genetics who received $614,400 for her project to develop a novel system for studying how stem cells become rare immune cells; Dr. Denis Evseenko, assistant professor of orthopedic surgery, who received $1,146,468 for his project to identify the elements of the biological niche in which stem cells grow most efficiently into articular cartilage cells; Dr. Thomas Otis, professor and chair of neurobiology and Dr. Ben Novitch, assistant professor of neurobiology, who received $1,148,758 for their project using new light-based optigenetic techniques to study the communication between nerve and muscle cells in spinal muscular atrophy, an inherited degenerative neuromuscular disease in children; and Dr. Samantha Butler, assistant professor of neurobiology, received $598,367 for her project on discovering which molecular elements drive stem cells to become the neurons, or nerve cells, in charge of our sense of touch. These basic … Continue reading →

Welcome to the San Francisco Stem Cell Treatment Center For the investigational use of adipose (fat) derived mesenchymal stem cells for clinical and research and deployment. Please call (415) 345-0099, or email info@sfstemcellcenter.com to set up a complimentary 15-minute consultation so we may determine how our programs may fit your specific needs. Our staff will be delighted to answer your questions. We are now engaged in IRB approved studies looking into the treatment of the following conditions/illnesses: Our center is a research affiliate of Cell Surgical Network (CSN). SFSCTC uses adipose derived mesenchymal stem cells for deployment & clinical research. Early stem cell research has traditionally been associated with the controversial use of embryonic stem cells. The new focus is on non-embryonic adult mesenchymal stem cells which are found in a persons own blood, bone marrow and fat. Most stem cell treatment centers in the world are currently using stem cells derived from bone marrow. Recent technological advances enable SFSCTC to use adipose derived stem cells. Autologous stem cells from a persons own fat are easy to harvest safely under local anesthesia and are abundant in quantities up to 2500 times those seen in bone marrow. Originally posted here: San … Continue reading →

PUBLIC RELEASE DATE: 29-Jan-2014 Contact: Dr. Qiuwei Pan q.pan@erasmusmc.nl Society for Experimental Biology and Medicine Researchers at Erasmus University Medical Center Rotterdam, The Netherlands, led by Dr. Qiuwei Pan and Dr. Luc van der Laan, have discovered that spontaneous tumorigenic transformation of human mesenchymal stem/stromal cells (MSCs) can occur during cell culture expansion, although the frequency is relatively low and often only observed after extensive passage in culture. This report appears in the January 2014 issue of Experimental Biology and Medicine. Currently, MSCs are being widely investigated as a potential treatment for various diseases. According to ClinicalTrials.gov, over 350 clinical trials using MSCs have been registered by the end of 2013 (with a search of: mesenchymal stem cells). For cell transplantation, MSCs are often isolated from either the patient or from a third party donor, and then expanded in cell culture before therapeutic application. In fact, spontaneous transformation of primary cells in cell culture has been well-investigated over decades. Malignant transformation of murine and monkey MSCs has also recently been reported. The current study confirmed that spontaneous tumorigenic transformation of human MSCs can occur during cell culture expansion. This potentially has large implications for the clinical application of ex vivo … Continue reading →

January 29, 2014 - 17:55 AMT PanARMENIAN.Net - Stem cell researchers are heralding a "major scientific discovery", with the potential to start a new age of personalized medicine, BBC News reports. Scientists in Japan showed stem cells can now be made quickly just by dipping blood cells into acid. Stem cells can transform into any tissue and are already being trialled for healing the eye, heart and brain. The latest development, published in the journal Nature, could make the technology cheaper, faster and safer, according to the BBC. The human body is built of cells with a specific role - nerve cells, liver cells, muscle cells - and that role is fixed. However, stem cells can become any other type of cell, and they have become a major field of research in medicine for their potential to regenerate the body. Embryos are one, ethically charged, source of stem cells. Nobel prize winning research also showed that skin cells could be "genetically reprogrammed" to become stem cells (termed induced pluripotent stem cells). Now a study shows that shocking blood cells with acid could also trigger the transformation into stem cells - this time termed STAP (stimulus-triggered acquisition of pluripotency) cells. Dr … Continue reading →

Wednesday 29 January 2014 14.05 A "revolutionary" new approach to creating stem cells in the laboratory could open up a new era of personalised medicine, it is claimed. Scientists have shown it is possible to reprogramme cells into an embryonic-like state simply by altering their environment. It means in principle that cells can have their developmental clock turned back without directly interfering with their genes - something never achieved before. The cells become "pluripotent", having the potential ability to transform themselves into virtually any kind of tissue in the body, from brain to bone. Reprogramming a patient's own cells in this way is seen as the Holy Grail of regenerative medicine. It raisesthe prospect of repairing diseased and damaged organs with new healthy tissue that will not be rejected by the immune system. Current methods of performing the same trick involve genetic manipulation, which carries with it a serious risk of triggering cancer. But the new method described in the journal Nature requires no genetic tweaking. Scientists simply bathed immature white blood cells from mice in an acidic solution for 25 minutes. View original post here: Scientists in revolutionary stem cell discovery … Continue reading →

Summary: Osiris reported break-even earnings in the third quarter of 2013, well above the Zacks Consensus Estimate of a loss of $0.09 and the year-ago loss of a penny per share. Revenues for the quarter came in at $6.9 million, in line with the Zacks Consensus Estimate and above the year-ago revenues of $2.2 million. In early Oct 2013, Osiris sold its culture-expanded mesenchymal stem cell (ceMSC) business including Prochymal to a wholly-owned subsidiary of Mesoblast Limited. This deal has not only brought in cash for Osiris in the form of an upfront payment, the company will also be entitled to royalty payments. We are moving back to a Neutral recommendation as we believe the current price reflects the afore-mentioned positive developments. Overview: Columbia, Md.-based Osiris Therapeutics, Inc. focuses on the development, manufacture and sale of biologic products which have been developed to promote the body's natural healing process and improve surgical outcomes. Currently marketed products include Grafix, Ovation, OvationOS and Cartiform for tissue repair. In Oct 2013, Osiris sold off its culture-expanded mesenchymal stem cell (ceMSC) business including Prochymal to a wholly-owned subsidiary of Mesoblast Limited for up to $100 million. Osiris will also be entitled to receive single … Continue reading →

Published Monday, 27 January 2014 A young teenager with diabetes tests his blood levels. (UTV) Scientists behind the new facility at the National University of Ireland Galway will aim to produce adult cells to combat conditions like diabetes, arthritis and heart disease. Stem cells created at the lab will be used in clinical trials following regulatory approval - the first of which is to test their effects on critical limb ischemia, a common complication associated with diabetes which often results in amputation. The cells, mesenchymal stem cells (MSCs), will undergo safety tests after being isolated from bone marrow from donors and grown in the laboratory to generate sufficient quantities. The university said it will position it as a global player in regenerative medicine. NUI Galway's Centre for Cell Manufacturing Ireland is the first facility on the island of Ireland to receive a licence from the Irish Medicines Board to manufacture culture-expanded stem cells for human use. It is one of less than half a dozen in Europe authorised for the process. Some 70% of pharmaceutical companies have regenerative medicine therapies in development, with 575 active trials in cell and gene therapy under way. There are more than 1,900 cell therapy … Continue reading →

AAP Scientists in Ireland aim to produce adult cells to combat conditions like arthritis. Stem cells for human use are to be made in a university lab in the first medical program of its kind in Ireland. Scientists behind the new facility at the National University of Ireland (NUI) Galway will aim to produce adult cells to combat conditions like arthritis, heart disease and diabetes. Stem cells created at the lab will be used in clinical trials following regulatory approval - the first of which is to test their effects on critical limb ischemia, a common complication associated with diabetes which often results in amputation. The cells, mesenchymal stem cells (MSCs), will undergo safety tests after being isolated from bone marrow from donors and grown in the laboratory to generate sufficient quantities. The university said it will position it as a global player in regenerative medicine. NUI Galway's Centre for Cell Manufacturing Ireland is the first facility in Ireland to receive a licence from the Irish Medicines Board to manufacture culture-expanded stem cells for human use. And it is one of less than half a dozen in Europe authorised for the process. "Developing Galway's role as med-tech hub of global … Continue reading →

27/01/2014 - 09:35:51Back to Ireland Home Stem cells for human use are to be made in a university lab in the first medical programme of its kind in Ireland. Scientists behind the new facility at the National University of Ireland Galway will aim to produce adult cells to combat conditions like arthritis, heart disease and diabetes. Stem cells created at the lab will be used in clinical trials following regulatory approval the first of which is to test their effects on critical limb ischemia, a common complication associated with diabetes which often results in amputation. The cells, mesenchymal stem cells (MSCs), will undergo safety tests after being isolated from bone marrow from donors and grown in the laboratory to generate sufficient quantities. The university said it will position it as a global player in regenerative medicine. NUI Galways Centre for Cell Manufacturing Ireland is the first facility on the island of Ireland to receive a licence from the Irish Medicines Board to manufacture culture-expanded stem cells for human use. And it is one of less than half a dozen in Europe authorised for the process. President of NUI Galway Dr Jim Browne said: Developing Galways role as med-tech hub of … Continue reading →

Philadelphia, PA (PRWEB) January 23, 2014 Bioquark, Inc., (http://www.bioquark.com) a company focused on the development of combinatorial biologics for regeneration and disease reversion in human organs and tissues, today announces the appointment of Dr. Joel I. Osorio MD, as VP of International Clinical Development. We are honored to have someone with Dr. Osorios experience join us as we execute on a globalized clinical strategy, said Ira S. Pastor, CEO, Bioquark Inc. His broad clinical experience in functional anti-aging regenerative and stem cell based medicine make him a very valuable addition to the Bioquark team. Dr. Osorio brings over 9 years of experience in medical practice, both in the private practice and public medical settings. Currently the medical director of the medical spa Bamboo Rejuvenecimiento Facial y Coporal (http://www.bamboobelleza.com), Dr. Osorio has served in capacities in both private and public practice, as a hospital staff physician, and as emergency health services coordinator for a variety of private and public institutions throughout Mexico. He earned MD degrees at both Westhill University and the National Autonomous University of Mexico as a medical surgeon, has diplomas in aesthetic medicine from the Autonomous University of Guadalajara, is an Advance Fellow by the American Board of … Continue reading →